ERBB2 and cancer: We demonstrated that the mPEG × HER2-modified PLD can significantly enhance its tumor targeted specificity, endocytic efficiency and cytotoxicity to HER2-overexpressed SKOV-3 cells and also increase its accumulation and anti-cancer activity in a HER2+ tumor-xenografted mouse model.